One year later, Fadini et al. demonstrated that in patients with type 2 diabetes (T2D), the reduced baseline levels of circulating CD34+ stem cells were a long-time (up to 6 years) predictive biomarker of adverse CV outcomes [33]. This evidence concerns the gene CD34 and type 2 diabetes mellitus.